Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis

To date, there are no inhibitors that directly and specifically target activated STAT3 and c-Myc in the clinic. Although peptide-based inhibitors can selectively block activated targets, their clinical usage is limited because of low cell penetration and/or serum stability. Here, we generated cell-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Aftabizadeh, Maryam, Li, Yi-Jia, Zhao, Qianqian, Zhang, Chunyan, Ambaye, Nigus, Song, Jieun, Nagao, Toshikage, Lahtz, Christoph, Fakih, Marwan, Ann, David K., Yu, Hua, Herrmann, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934871/
https://www.ncbi.nlm.nih.gov/pubmed/33491667
http://dx.doi.org/10.1172/jci.insight.136176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934871/
https://www.ncbi.nlm.nih.gov/pubmed/33491667
http://dx.doi.org/10.1172/jci.insight.136176

Ejemplares similares